Ahirwar Dinesh K, Agrahari Anita, Mandhani Anil, Mittal Rama D
Department of Urology and Renal Transplantation, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India.
Biomarkers. 2009 Jun;14(4):213-8. doi: 10.1080/13547500902818246.
The association of interleukin-1beta (IL-1B) -511C > T and IL-1 receptor antagonist (IL-1RN) VNTR, transforming growth factor-beta (TGF-B1) +28C > T and interferon-gamma (IFN-G) + 874T>A polymorphisms with bladder cancer (CaB) susceptibility and risk of recurrence in Bacillus Calmette-Guérin (BCG)-treated patients was analyzed in 287 controls and 213 CaB patients (73 BCG treated). Increased risk was observed with the IL-1RN*2 allele (odds ratio (OR) 5.01) and the IFN-G +874 A allele (OR 1.78). TGF-B TT and IFN-G +874 A carriers were associated with reduced (hazard ratio (HR) 0.37) and enhanced (HR 2.24) risk of recurrence after BCG immunotherapy, respectively. The study suggests that cytokine gene variants may modulate CaB susceptibility and risk of recurrence after BCG immunotherapy.
在287名对照者和213名膀胱癌（CaB）患者（73名接受卡介苗（BCG）治疗）中，分析了白细胞介素-1β（IL-1B）-511C>T、白细胞介素-1受体拮抗剂（IL-1RN）可变数目串联重复序列（VNTR）、转化生长因子-β（TGF-B1）+28C>T和干扰素-γ（IFN-G）+874T>A多态性与CaB易感性以及BCG治疗患者复发风险的关系。观察到携带IL-1RN*2等位基因（比值比（OR）5.01）和IFN-G +874 A等位基因（OR 1.78）的风险增加。TGF-B TT携带者和IFN-G +874 A携带者分别与BCG免疫治疗后复发风险降低（风险比（HR）0.37）和增加（HR 2.24）相关。该研究表明，细胞因子基因变异可能会调节CaB易感性以及BCG免疫治疗后的复发风险。
